急性骨髄性白血病の治療薬市場。世界の産業動向、シェア、サイズ、成長、機会、予測2021-2026年Acute Myeloid Leukemia Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global acute myeloid leukemia therapeutics market grew at a CAGR of around 7% during 2015-2020. Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnorma... もっと見る
サマリーThe global acute myeloid leukemia therapeutics market grew at a CAGR of around 7% during 2015-2020. Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further. Looking forward, IMARC Group expects the global acute myeloid leukemia therapeutics market to exhibit moderate growth during the next five years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global acute myeloid leukemia therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, drug type and route of administration. Breakup by Treatment Type: Cytarabine Anthracycline Drugs Alkylating Agents Anti-Metabolites Tyrosine Kinase Inhibitors Others Breakup by Drug Type: Small Molecule Drugs Biopharmaceuticals Breakup by Route of Administration: Oral Injectables Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc. , Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited. Key Questions Answered in This Report: How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market? What are the key regional markets? What is the breakup of the market based on the treatment type? What is the breakup of the market based on the drug type? What is the breakup of the market based on the route of administration? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Acute Myeloid Leukemia Therapeutics Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Treatment Type 6.1 Cytarabine 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Anthracycline Drugs 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Alkylating Agents 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Anti-Metabolites 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Tyrosine Kinase Inhibitors 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Others 6.6.1 Market Trends 6.6.2 Market Forecast 7 Market Breakup by Drug Type 7.1 Small Molecule Drugs 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Biopharmaceuticals 7.2.1 Market Trends 7.2.2 Market Forecast 8 Market Breakup by Route of Administration 8.1 Oral 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Injectables 8.2.1 Market Trends 8.2.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbvie Inc. 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Amgen Inc. 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Bristol-Myers Squibb Company 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 Celgene 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 SWOT Analysis 14.3.5 Roche Holding AG 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.6 Gilead Sciences Inc. 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 Novartis AG 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.8 Pfizer Inc. 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Sanofi S.A. 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.10 Takeda Pharmaceutical Company Limited 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis
SummaryThe global acute myeloid leukemia therapeutics market grew at a CAGR of around 7% during 2015-2020. Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further. Looking forward, IMARC Group expects the global acute myeloid leukemia therapeutics market to exhibit moderate growth during the next five years. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global acute myeloid leukemia therapeutics market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, treatment type, drug type and route of administration. Breakup by Treatment Type: Cytarabine Anthracycline Drugs Alkylating Agents Anti-Metabolites Tyrosine Kinase Inhibitors Others Breakup by Drug Type: Small Molecule Drugs Biopharmaceuticals Breakup by Route of Administration: Oral Injectables Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc. , Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited. Key Questions Answered in This Report: How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market? What are the key regional markets? What is the breakup of the market based on the treatment type? What is the breakup of the market based on the drug type? What is the breakup of the market based on the route of administration? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Acute Myeloid Leukemia Therapeutics Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Treatment Type 6.1 Cytarabine 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Anthracycline Drugs 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Alkylating Agents 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 Anti-Metabolites 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Tyrosine Kinase Inhibitors 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Others 6.6.1 Market Trends 6.6.2 Market Forecast 7 Market Breakup by Drug Type 7.1 Small Molecule Drugs 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Biopharmaceuticals 7.2.1 Market Trends 7.2.2 Market Forecast 8 Market Breakup by Route of Administration 8.1 Oral 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Injectables 8.2.1 Market Trends 8.2.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbvie Inc. 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.1.3 Financials 14.3.1.4 SWOT Analysis 14.3.2 Amgen Inc. 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Bristol-Myers Squibb Company 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 Financials 14.3.3.4 SWOT Analysis 14.3.4 Celgene 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 SWOT Analysis 14.3.5 Roche Holding AG 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.5.3 Financials 14.3.6 Gilead Sciences Inc. 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 Novartis AG 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.8 Pfizer Inc. 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.8.3 Financials 14.3.8.4 SWOT Analysis 14.3.9 Sanofi S.A. 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.10 Takeda Pharmaceutical Company Limited 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 Financials 14.3.10.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(中枢神経系作用薬)の最新刊レポート
IMARC Services Private Limited.社の中枢神経系作用薬分野での最新刊レポート本レポートと同じKEY WORD(acute)の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/13 10:29 155.97 円 166.03 円 201.39 円 |